✨ Free AI Report
Cepheid: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Cepheid
Research Preview

Cepheid: Business Overview, Financials & Competitive Analysis

Cepheid is a molecular diagnostics company owned by Danaher Corporation that develops, manufactures, and markets fully-integrated systems for genetic analysis. The company's GeneXpert platform automates sophisticated ...

Analyst-debate audio for Cepheid

AskCyborg analysts argue the bull and bear cases for Cepheid across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cepheid OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Solid

Cyborg Score thesis

Market leader in automated molecular diagnostics benefiting from parent company resources and expanding clinical applications in...

Read the full analyst-debate transcript →
Industry In-Vitro Diagnostics
6 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Cepheid Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cepheid Overview

Pro stress-test →

Cepheid is a molecular diagnostics company owned by Danaher Corporation that develops, manufactures, and markets fully-integrated systems for genetic analysis. The company's GeneXpert platform automates sophisticated molecular testing across clinical, industrial, and biothreat markets, enabling rapid detection of infectious diseases and genetic conditions from diverse sample types.

Strategic Profile

Pro stress-test →

Cepheid leverages automation and ease-of-use as core competitive advantages, reducing manual laboratory procedures and enabling decentralized testing. As a Danaher subsidiary since 2016, it benefits from parent company scale and resources while focusing on expanding its molecular diagnostics portfolio, including recent CE marking achievements for gastrointestinal pathogen detection panels.

Competitive Landscape

Pro stress-test →

Cepheid competes in molecular diagnostics against companies like Bio-Rad, BioMérieux, Qiagen, and Abbott Diagnostics. Its competitive advantage rests on the automated, easy-to-use GeneXpert platform ecosystem, which reduces manual steps and enables rapid results. Competitors typically emphasize throughput, multiplex capacity, or laboratory automation, while Cepheid targets decentralized, rapid testing across diverse clinical settings.

Industry Context

Cepheid operates in In-Vitro Diagnostics.

Key facts

Founded: 1996 · Headquarters: Sunnyvale, US · Employees: Unknown · Revenue: Estimated $800M-$1B (subsidiary of Danaher; standalone figures unavailable post-delisting) · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Cepheid.

+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Cepheid has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Abbott DiagnosticsMolecular diagnostics and rapid testing systems→QiagenMolecular testing solutions and sample analysis platforms→BioMérieuxClinical diagnostics and microbiology testing systems→Roche DiagnosticsMolecular diagnostics and automated laboratory testing systems→HologicMolecular diagnostics and laboratory-based testing analyzers→Siemens HealthineersMolecular diagnostics and laboratory analyzer systems→

Compare Cepheid with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cepheid operates in In-Vitro Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse In-Vitro Diagnostics research →
NEW · MCP server

Ask your AI assistant about Cepheid

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cepheid and its top competitor on Cyborg Score”
“What did Cepheid do this quarter?”
“Is Cepheid a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Cepheid do?+
Cepheid is a molecular diagnostics company owned by Danaher Corporation that develops, manufactures, and markets fully-integrated systems for genetic analysis. The company's GeneXpert platform automates sophisticated ...
What is Cepheid's Cyborg Score?+
Cepheid has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cepheid's main competitors?+
Named competitors include Abbott Diagnostics, Qiagen, BioMérieux, Roche Diagnostics. The full competitive landscape is in the AskCyborg report.
How can I get the full Cepheid research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cepheid research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cepheid over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In-Vitro Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7DiaSorin S.p.A.7Shenzhen New Industries Biomedical Engineering Co., Ltd.4Biosynex SA6Hologic, Inc.